Drug Profile
Research programme: dronabinol controlled-release - Aphios Corporation
Alternative Names: APH-0802; Cannabinoid therapeutics - Aphios Corporation; nanoTHC™Latest Information Update: 28 Dec 2017
Price :
$50
*
At a glance
- Originator Aphios Corporation
- Class Cannabinoids
- Mechanism of Action Cannabinoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cachexia; Cancer pain; Multiple sclerosis; Nausea and vomiting; Pain; Substance-related disorders
Highest Development Phases
- No development reported Cachexia; Cancer pain; Chemotherapy-induced nausea and vomiting; Multiple sclerosis; Pain; Substance-related disorders
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (PO, Controlled release)
- 28 Dec 2017 No recent reports of development identified for preclinical development in Pain in USA (PO, Controlled release)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cachexia in USA (PO, Controlled release)